Recent News

• 08.11.2026 - NeurAxis Reports Record Second Quarter 2026 Financial Results Driven by 116% Year Over Year Revenue Growth
• 08.04.2026 - NeurAxis Expands Payer Coverage with New Policies
• 07.28.2026 - NeurAxis to Host Second Quarter 2026 Results and Business Update Call on Tuesday, August 11, 2026
• 04.22.2026 - NeurAxis Expands Payer Coverage with Four New Medical Policies
• 04.10.2026 - NeurAxis, Inc. Announces Preferred Stock Dividend
• 03.19.2026 - NeurAxis Reports Strong Fourth Quarter and Full Year 2025 Financial Results
• 03.12.2026 - NeurAxis to Host Fourth Quarter and Full Year 2025 Results and Business Update Call on Thursday, March 19, 2026
• 01.08.2026 - NeurAxis Achieves Major Milestone with AMA Category I CPT® Code Now in Effect, Establishing a Permanent Reimbursement Pathway
• 12.01.2025 - NeurAxis Secures Veterans Affairs Federal Supply Schedule Contract, Broadening Access to More Patients with Functional Abdominal Pain
• 11.12.2025 - NeurAxis Announces New Medical Policy Coverage in Michigan, Adding 566,000 Covered Lives

Recent Filings

• 08.11.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.06.2026 - 424B3 Prospectus [Rule 424(b)(3)]
• 08.03.2026 - EFFECT Notice of Effectiveness
• 08.03.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 07.30.2026 - S-3/A Registration statement under Securities Act of 1933
• 07.23.2026 - S-3 Registration statement under Securities Act of 1933
• 07.10.2026 - 8-K Current report
• 07.10.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 06.12.2026 - 8-K Current report
• 05.12.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]